DENVER, Oct. 20 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disorders, today announced that it will report 2005 third
quarter results the afternoon of Wednesday, November 2, 2005.
J. William Freytag, President and CEO, and other members of Myogen's
senior management will provide a company update and discuss results via
webcast and conference call on Wednesday, November 2, 2005 at 4:30 pm Eastern.
To access the live webcast, please log on to the company's website at
http://www.myogen.com and go to the Investor Relations section. Alternatively,
callers may participate in the conference call by dialing 800-257-1927
(domestic) or 303-205-0066 (international). Webcast and telephone replays of
the conference call will be available approximately two hours after the
completion of the call through Wednesday, November 16, 2005. Callers can
access the replay by dialing 800-405-2236 (domestic) or 303-590-3000
(international). The passcode is 11042459#.
About Myogen
Myogen currently markets one product (Perfan(R) I.V.) in Europe for the
treatment of acute decompensated heart failure and has two product candidates
in late-stage clinical development: ambrisentan for the treatment of patients
with pulmonary arterial hypertension and darusentan for the treatment of
patients with resistant hypertension. The company, in collaboration with
Novartis, also conducts a target and drug discovery research program focused
on the development of disease-modifying drugs for the treatment of chronic
heart failure and related cardiovascular disorders. Please visit our website
at http://www.myogen.com.
Safe Harbor Statement
The 2005 third quarter results press release and conference call will
contain forward-looking statements that involve significant risks and
uncertainties, including those that can be found in the "Risk Factors" section
of Myogen's Form 10-K for the year ended December 31, 2004 and in Myogen's
periodic reports on Form 10-Q and Form 8-K. Myogen is providing the
information contained in the release and conference call as of the date of the
release and does not undertake any obligation to update any forward-looking
statements as a result of new information, future events or otherwise. The
company cautions investors not to place undue reliance on the forward-looking
statements contained in the press release or the conference call. No
forward-looking statement can be guaranteed and actual events and results may
differ materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
